Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Venmax Drugs & Pharmaceuticals Quick Ratio?
Venmax Drugs & PharmaceuticalsBOM:531015 +1.88%33 Quick Ratio is 7.46 as of Mar. 2026, which is 12333% above its 10-year median of 0.06. GuruFocus rates BOM:531015 with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Venmax Drugs & Pharmaceuticals ranks better than 92.79% on this metric.
Venmax Drugs & Pharmaceuticals has a quick ratio of 7.46. It generally indicates good short-term financial strength.
The historical rank and industry rank for Venmax Drugs & Pharmaceuticals's Quick Ratio or its related term are showing as below:
BOM:531015'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.06 Max: 7.46
Current: 7.46
During the past 13 years, Venmax Drugs & Pharmaceuticals's highest Quick Ratio was 7.46. The lowest was 0.02. And the median was 0.06.
BOM:531015's Quick Ratio is ranked better than 92.79% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.445
vs BOM:531015: 7.46
Venmax Drugs & Pharmaceuticals (BOM:531015) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Venmax Drugs & Pharmaceuticals Quick Ratio Related Terms
Venmax Drugs & Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venmax Drugs & Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venmax Drugs & Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venmax Drugs & Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Venmax Drugs & Pharmaceuticals's Quick Ratio falls into.
Venmax Drugs & Pharmaceuticals Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venmax Drugs & Pharmaceuticals (BOM:531015) has a Quick Ratio of 7.46 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. This is 12333% above median its historical median of 0.06. Over the past decade, Venmax Drugs & Pharmaceuticals' Quick Ratio has ranged from 0.02 to 7.46. According to the industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #72 out of 998 companies in the Drug Manufacturers industry, placing it in the top 7.2%.
Is Venmax Drugs & Pharmaceuticals' Quick Ratio too high?
Venmax Drugs & Pharmaceuticals' current Quick Ratio of 7.46 is 12333% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 7.46. The Drug Manufacturers industry median Quick Ratio is 1.45. Venmax Drugs & Pharmaceuticals' value of 7.46 is 416.3% above this industry median. Based on the distribution chart, Venmax Drugs & Pharmaceuticals ranks #72 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Venmax Drugs & Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Venmax Drugs & Pharmaceuticals' Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #72 out of 998 companies for Quick Ratio. This places Venmax Drugs & Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Venmax Drugs & Pharmaceuticals' value of 7.46 is 416.3% above this benchmark. Historically, Venmax Drugs & Pharmaceuticals' own Quick Ratio has ranged from 0.02 to 7.46 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 1.45, Venmax Drugs & Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venmax Drugs & Pharmaceuticals's current Quick Ratio of 7.46 is 416.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venmax Drugs & Pharmaceuticals's current Quick Ratio is 7.46, which is 12333% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venmax Drugs & Pharmaceuticals stock overvalued right now?
Venmax Drugs & Pharmaceuticals (BOM:531015) has a current Quick Ratio of 7.46. The current Quick Ratio is 7.46, which is 12333% above median its 10-year median of 0.06 and 416.3% above the Drug Manufacturers industry median of 1.45. Venmax Drugs & Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Venmax Drugs & Pharmaceuticals (BOM:531015), the current Quick Ratio is 7.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Venmax Drugs & Pharmaceuticals Business Description
Venmax Drugs & Pharmaceuticals Ltd is engaged in the manufacturing and sale of bulk drugs. The company is engaged in the business of IT & ITES services.
33GF Score
Get the complete analysis for BOM:531015
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531015 has been successfully added to your 
